← Pulse/Companies

Triveni Bio on Pulse

Biotech

The full thread of our Triveni Bio coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jun 17, 2026
Since

Coverage Timeline

newest first
  1. FUNDINGTriveni Bio Raises $65M for Antibody Therapeutics in Immunology→
  2. FUNDINGTriveni Bio Raises $65M for Antibody-Based Immunology Therapeutics→

All Coverage

FUNDING$65M

Triveni Bio Raises $65M for Antibody Therapeutics in Immunology

Triveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.

Jun 18, 2026
FUNDING$65M

Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics

Triveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.

Jun 17, 2026